Table 1: Base-case cost-effectiveness results
InterventionCost, $No. of life-yearsNo. of QALYsIncremental $/life-year gainedIncremental $/QALY gained
PIAAF-Pharmacy screening443.999.0276.880
No screening417.939.0236.876
Incremental26.060.00320.003582137480

Note: PIAAF-Pharmacy = Program for the Identification of 'Actionable' Atrial Fibrillation in the Pharmacy Setting, QALY = quality-adjusted life-year.